NEURO-TTR phase 3 open-label extension study showed TEGSEDI® (inotersen) treatment continued to slow progression over two-year period in patients with Hereditary ATTR amyloidosis with polyneuropathy.

Greater efficacy and clinical benefit observed with early initiation of TEGSEDI and no new safety signals with longer duration of treatment.

For more information, click here